Summary
Analyzes patent landscapes, regulatory exclusivity timelines, and freedom-to-operate considerations for drug development programs.
Detailed Description
The Patent & Exclusivity Intelligence Pack provides strategic intellectual property intelligence for drug development programs. It maps the patent landscape around your therapeutic target, mechanism of action, and formulation approach, and tracks regulatory exclusivity timelines for competing products to inform development and commercial strategy.
The pack aggregates patent databases, Orange Book and Purple Book listings, Paragraph IV certification history, and published patent litigation outcomes to provide a comprehensive IP landscape analysis. It identifies potential freedom-to-operate issues, upcoming patent cliffs for competitors, and exclusivity expiration timelines that may create market opportunities.
Deliverables include a patent landscape analysis, an exclusivity timeline map for your therapeutic area, and a freedom-to-operate risk assessment highlighting potential IP barriers and mitigation strategies.
Evidence Sources
| Source | Type | Description | Refresh |
|---|---|---|---|
| Patent Database | IP | USPTO, EPO, and WIPO patent databases with full-text search and citation analysis | Weekly |
| Orange/Purple Book | REGULATORY | FDA Orange Book (small molecules) and Purple Book (biologics) with patent and exclusivity listings | Monthly |
| Patent Litigation Database | LEGAL | Database of Paragraph IV certifications, ANDA/BLA patent challenges, and litigation outcomes | Weekly |
Regulatory Mapping
Approved Drug Products with Therapeutic Equivalence Evaluations
Lists of Licensed Biological Products with Reference Product Exclusivity
Drug Price Competition and Patent Term Restoration Act
Agent Transparency
When you run this pack, your request is processed by a pipeline of specialized AI agents. Each agent operates with a defined confidence threshold and is auditable end-to-end.
Evidence Retriever
brew-retriever-v3
Queries curated sources for relevant evidence objects. Searches across regulatory databases, clinical registries, and scientific literature to surface the most pertinent references for the pack domain.
Domain Analyzer
brew-domain-analyst-v2
Applies domain-specific reasoning and regulatory mapping. Interprets evidence in the context of FDA, ICH, and EMA frameworks and tags each finding with the relevant guidance references.
Evidence Synthesizer
brew-synthesizer-v2
Synthesizes findings into structured output. Combines retrieved evidence and domain analysis into a cohesive narrative with quantitative summaries, comparative tables, and actionable recommendations.
Output Validator
brew-validator-v1
Validates citations, checks confidence thresholds, and ensures all referenced sources are accessible and correctly attributed. Flags any claims that fall below the confidence floor.
Sample Outputs
Patent Landscape Analysis
PDFComprehensive analysis of patents relevant to your target, mechanism, and formulation approach
Exclusivity Timeline Map
XLSXVisual timeline of regulatory exclusivity expirations for competing products in your therapeutic area
Freedom-to-Operate Assessment
PDFRisk assessment of potential IP barriers with mitigation strategies and design-around options
Deliverables included
- Patent landscape analysis for target and mechanism
- Regulatory exclusivity timeline map
- Freedom-to-operate risk assessment
- Paragraph IV certification history analysis
- Patent cliff opportunity analysis
Related Disease & Biomarker Mappings
| Therapeutic Area | Disease Family | Key Biomarkers | Relevance |
|---|---|---|---|
| Cross-Therapeutic | Pipeline Competitive Landscape | Market differentiation markers | Primary |
| Oncology | IO Competitive Landscape | PD-(L)1 AgentsLAG-3TIGIT | Secondary |
Related Packs in Competitive Intelligence
Version History
Current release — expanded evidence sources, improved citation accuracy, and added new regulatory cross-references.
Beta release — validated with domain SMEs. Added sample output previews and refined confidence scoring.
Initial draft — core evidence retrieval pipeline and output schema established.
Need a Custom Evidence Pack?
Our enterprise team can build bespoke evidence packs tailored to your therapeutic area, regulatory strategy, or internal decision framework. Custom packs include dedicated evidence source curation, domain-specific agent tuning, and priority SLA support.
Enterprise packs are available for organizations on the BrewBio Pro or Enterprise plan.